Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of bivalent rLP2086 meningococcal B vaccine in healthy children aged 2 to under 10 years
2014-000933-21Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of meningococcal group B recombinant lipoprotein 2086 vaccine in meningococcal disease and meningococcal meningitis (2 arms), sponsored by Pfizer. Primary endpoints: Immune response by hSBA in subjects aged at least 24 months to under 4 years and Immune response by hSBA in combined subjects aged at least 24 months to under 10 years. Started Apr 2015; status: completed.
02
Drugs
meningococcal group B recombinant lipoprotein 2086 vaccine
03
Conditions
meningococcal diseasemeningococcal meningitis
Beyond the preview
Go deeper on 2014-000933-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000933-21.